新华财经北京12月31日电（胡晨曦） 在BD（商务拓展）出海大单持续超预期等催化下，创新药板块 2025年表现亮眼。尽管近期连续调整，但港股创新药指数（931787.CSI）等创新药代表性指数年内涨幅 仍近70%。个股方面，截至A股12月31日收盘，舒泰神、三生国健、荣昌生物、昭衍新药等个股股价年 内实现翻倍。 展望2026年，业内人士普遍看好在产业政策对真创新、高水平创新的支持下，大量创新药BD将密集落 地。商保实施与集采优化双轮推动下，创新药产业链高景气度有望延续，高价值创新药有望迎来第二增 长曲线。 个股表现抢眼医药企业蜂拥港股 今年以来，二级市场上创新药板块表现十分亮眼。 其中，A股方面，截至12月31日收盘，舒泰神、三生国健、荣昌生物、昭衍新药等个股股价实现翻倍， 其中舒泰神年内股价曾一度暴涨近7倍。港股方面，年初至今，荣昌生物、三生制药涨超300%，信达生 物、翰森制药、诺诚健华、药明合联等多股涨超100%。此外，2025年初至今，港股创新药指数 （931787.CSI）涨约72.5%，其间一度飙升逾100%。A股创新药板块同样大涨，1月10日至9月8日，中证 创新药（931152.CSI）指数累 ...

Key Takeaways VNDA won FDA approval for tradipitant, branded Nereus, to prevent vomiting caused by motion sickness.Vanda Pharmaceuticals said Nereus is the first new motion sickness drug in more than 40 years.VNDA shares surged 18% after hours following the approval, extending gains into pre-market trading.Vanda Pharmaceuticals, Inc. (VNDA) announced that the FDA has approved its candidate tradipitant for the prevention of vomiting induced by motion.The drug has been approved under the brand name Nereus.Tra ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets delivered solid results in the third quarter, driven by the resolution of significant trade conflicts and a shift in U.S. monetary policy toward a more dovish stance. Baird Chautauqua International Growth Fund underperformed the ...

Key Takeaways BMY's growth portfolio rose 17% in the first nine months, while legacy drug sales fell 16% on generics.BMY's Opdivo momentum and Qvantig approval support projected high single- to low double-digit growth.BMY's Reblozyl topped a $2B run rate, Breyanzi passed $1B, while legacy drugs still made up 47% of sales.Bristol Myers Squibb’s (BMY) performance in 2025 reflects an ongoing transition in its revenue base, with growth from newer products partially offsetting continued declines in legacy drugs. ...

Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and CEO of Novo Nordisk. ...

Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and CEO of Novo Nordisk. ...

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' hormone-blocking drug for the treatment of a rare hormonal disorder, the company said on Wednesday. ...

Blackstone makes most of its money from management and advisory fees, and performance allocations. Management fees are stable, recurring fees charged to investors (such as pension funds and sovereign wealth funds) as a percentage of the total assets under management or committed capital. In the third quarter of 2025, Blackstone's management and advisory fees surpassed a record $2 billion, a 14% year-over-year increase.The company is also the world's largest owner of commercial real estate . It owns thousand ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment fo. ...

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics throu ...